Table 1 Baseline characteristics in patients who received prescriptions for mirabegron or antimuscarinicsa
Mirabegron (N = 1169) | Antimuscarinics (N = 629) | Total (N = 1798) | |
|---|---|---|---|
Sex, N (%) | |||
Male | 532 (45.5) | 245 (39.0) | 777 (43.2) |
Female | 637 (54.5) | 384 (61.0) | 1021 (56.8) |
Age, mean (SD) | 66.31 (13.41) | 66.61 (14.71) | 66.42 (13.88) |
Age category, N (%) | |||
< 65 years | 414 (35.4) | 235 (37.4) | 649 (36.1) |
65–80 years | 617 (52.8) | 277 (44.0) | 894 (49.7) |
> 80 years | 138 (11.8) | 117 (18.6) | 255 (14.2) |
BMI, mean (SD) | 30.15 (5.47) | 29.88 (5.62) | 30.06 (5.52) |
BMI category, N (%)b | |||
Underweight (< 18.5) | 4 (0.5) | 5 (1.3) | 9 (0.8) |
Normal or healthy weight (18.5–24.9) | 137 (17.3) | 64 (16.2) | 201 (17.0) |
Overweight (25.0–29.9) | 277 (35.1) | 153 (38.7) | 430 (36.3) |
Obese (≥30.0) | 372 (47.1) | 173 (43.8) | 545 (46.0) |
Treatment status, N (%) | |||
Treatment-naïve | 750 (64.2) | 539 (85.7) | 1289 (71.7) |
Treatment-experienced | 419 (35.8) | 90 (14.3) | 509 (28.3) |
Prior treatment with α-blockers, N (%)c | |||
Yes | 157 (13.4) | 58 (9.2) | 215 (12.0) |
No | 1012 (86.6) | 571 (90.8) | 1583 (88.0) |
Prescriber at index date, N (%) | |||
Gynaecologist/urologist | 749 (64.1) | 131 (20.8) | 880 (48.9) |
GP | 397 (34.0) | 476 (75.7) | 873 (48.6) |
Other | 23 (2.0) | 22 (3.5) | 45 (2.5) |
Type of care for prescribed index drug, N (%) | |||
Primary | 397 (34.0) | 476 (75.7) | 873 (48.6) |
Secondary | 23 (66.1) | 22 (24.3) | 45 (51.4) |